The venture capital spending spree in 2020 has led to many notably large biopharmaceutical company funding rounds, making $100m-plus mega-rounds less surprising than they used to be. The latest entrants to the mega-round club include China-focused specialty drug developer Nuance Pharma and San Diego-based radiopharmaceutical specialist RayzeBio, Inc.
Cancer and immuno-oncology continue to generate a lot of investor interest, but recent mega-rounds have backed a diverse array of...






